Sandoz to acquire Just – Evotec Biologics Toulouse site from Evotec for $350m.

Sandoz, a company that focuses on generic pharmaceuticals and biosimilars, agreed to acquire Just – Evotec Biologics Toulouse site, a biomanufacturing facility, from Evotec, a life science company, for $350m. “This is a transformative milestone for Evotec as we further leverage Just – Evotec Biologics’ capabilities and position the company as a scalable technology provider. With our unique offering, we are expanding the scope of addressable partners and shaping a new segment in the biologics manufacturing market in a very capital efficient way. Additionally, with this transaction, Evotec is delivering on its asset lighter strategy, sharpening its focus on its core strengths, and is well on track for sustainable and profitable growth," Christian Wojczewski, Evotec CEO.